Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Virology
Rosetta Genomics and Ben Gurion University to Develop Microrna-Based Therapeutic Applications for Key Infectious Diseases Based on Viral Micrornas Discovered by Rosetta Genomics
August 14th, 2007
Rosetta Genomics (Nasdaq:ROSG), a leading RNAi company, announced it has signed a collaboration agreement with Ben Gurion University, through B.G Negev Technologies, focusing on the development of microRNA-based therapeutic applications for several key viruses including the Epstein-Barr virus (EBV) and Herpes Simplex Viruses (HSV). The central role microRNAs and RNAi play in a wide range of cellular processes, as well as the link between their aberrant expression and the onset and progression of various viral diseases, point to microRNAs' potential as novel drug targets. A combined research team from Rosetta Genomics and of Ben Gurion University led by Dr. Yonat Shemer,...
Source: Virus Weekly (2007-08-14)
|
